Tvardi Therapeutics TVRD 深 沪
已收盘 08-21 16:00:00 美东时间
1.86
+0.030
+1.64%
华盛通- 最 高1.9295
- 今 开1.83
- 成交量 16.68万股
- 最 低 1.82
- 昨 收 1.83
- 总市值 2481.04万
- 52周最高 43.65
- 市盈率 静 --
- 换手率 1.25%
- 52周最低 1.50
- 委 比 10.71%
- 总股本 1333.89万
- 历史最高 1067.292
- 量 比 0.84
- 振 幅 5.98%
- 历史最低 1.50
- 每 手 1
- 风险率 11.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.70) by 1.43 percent. This is a 31 percent increase over losses of $(1.00) per share from the same period last year.
08-14 19:07
Tvardi Therapeutics To Host KOL Webinar On August 19 To Discuss Current Treatment Landscape In Ulcerative Colitis And Persistent Unmet Needs; Event To Feature New Data From Tvardi And Review Of Phase 1 Healthy Volunteer Results Supporting Potential Of TTI-109 In UC
Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that it will host a KOL webinar on Wed...
08-12 20:04
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5
BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $15 to $5.
07-31 03:05
美股大行评级 | 潜在涨幅215.37%！摩根士丹利上调TeraWulf(WULF)目标价至72美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从66.5美元升至72美元；HC Wainwright & Co.：维持Vera Therapeutics"买入"评级，目标价从110美元升至125美元
07-09 12:35
美股夜盘 | Republic Power涨38.76%，巨龙在线涨22.55%
Tvardi Therapeutics Inc.涨-10.80%；Dreamland涨-9.80%；有信科技涨-9.33%
07-09 08:05
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
BTIG Reiterates Buy on Tvardi Therapeutics, Maintains $15 Price Target
BTIG analyst Julian Harrison reiterates Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and maintains $15 price target.
07-08 00:57
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket
Shares of Universe Pharmaceuticals Inc (NASDAQ:UPC) rose sharply in pre-market trading after the company announced it will acquire Best Praise International for $10.75 million. Universe Pharmaceuticals shares jumped 228.4% to $9.72 in pre-market trading. Here are some other stocks moving in pre-mark...
06-29 19:03
美股夜盘 | Tvardi Therapeutics Inc.涨22.67%，最新股价1.84美元
Tvardi Therapeutics Inc.涨22.67%，报1.84美元
06-29 08:20
